| Starts |
Feb. 26, 2026, 5 p.m. |
| Ends |
Feb. 26, 2026, 6:30 p.m. |
Description
Register: https://docs.google.com/forms/d/e/1FAIpQLScNtWDQo0wmxj-F8LaSCm0idc3hVTogT2I9oQdDFkDLic7MxA/viewform?usp=header
This presentation explores a new approach to finding new medicines using data from millions of people. Instead of developing drugs in the traditional way, this method uses health records and genetic information combined together.
How it works:
The approach uses two key pieces of information: health data from large populations and genetic/molecular data (omics). By combining these, researchers can identify which genes or proteins might be good targets for new drugs.
Who benefits:
Doctors and hospitals get new treatment options for complex diseases that affect many body systems. Pharmaceutical and biotech companies get a better way to predict which drug targets will be approved by regulators. Researchers can use data science to predict how drugs will affect different diseases.
The big picture:
This method relies on having access to massive healthcare databases that include patient health records and genetic information. The UK Biobank is currently the best example of this type of combined dataset. However, large healthcare systems in Asia have the potential to become leaders in this field because they have access to even larger populations of patient data.
This approach could transform how we discover new medicines and understand disease.
[slug:population-scale-human-phenotypes-drug-targets-disease-feb-2026]